Haemato AG

HAEK.H maintains a strong liquidity position, with a current ratio of 2.59, indicating the company can cover its short-term liabilities more than two times over. The company holds EUR 23.81 million in cash and equivalents, which is a significant portion of its total assets of EUR 176.57 million. The liquidity_fpt metric confirms the company's ability to meet short-term obligations without external financing.

In terms of profitability, HAEK.H generates a return on equity (ROE) of 5.57% and a return on assets (ROA) of 4.64%. These figures are below the industry median for ROE and ROA in the pharmaceutical sector, suggesting the company is underperforming in asset and equity utilization relative to its peers. The operating margin is 3.34%, and the net profit margin is 3.30%, both of which are in line with the industry average.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic or regulatory shifts. The absence of segment-specific revenue breakdowns in the financial snapshot limits the ability to assess the performance of individual product lines or geographic regions.

Looking ahead, HAEK.H is projected to maintain a stable revenue trajectory, with no significant growth or decline expected in the next fiscal year. The company's capital expenditure is negative, indicating asset disposals or reduced investment in physical infrastructure. This may reflect a strategic shift toward cost optimization or a focus on intangible assets.

The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The debt-to-equity ratio is 0.04, suggesting a conservative capital structure with minimal reliance on debt financing. The company's free cash flow of EUR 2.72 million supports its operational flexibility and capacity to fund dividends or share repurchases.

Recent filings and transcripts do not highlight any material events or strategic shifts. The company's financial performance appears stable, with no significant changes in operating cash flow or net income. Analysts have assigned a mean price target of EUR 35.00, with a single "buy" recommendation and no "strong buy" or "hold" ratings.